C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia

May 11, 2017 updated by: Mohamed gamal, Assiut University

C-X-C Chemokine Receptor 4 as Prognostic Marker in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is the most common type of chronic leukemia, accounting for approximately 40% of all leukemias and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with chronic lymphocytic leukemia.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Prognosis depends primarily on the stage of the disease at diagnosis. There is a correlation between disease stage and median survival. However, about 50% of patients in early stage will develop more advanced disease. Also there is marked variation in disease progression amongst patients with similar Stages .

Extreme clinical heterogeneity is one of the hallmark features of chronic lymphocytic leukemia despite the identification of genetic and phenotypic markers that correlate with prognosis, the biological basis of this clinical variability remains unclear .. In addition, the interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote chronic lymphocytic leukemia cell survival and proliferation.

The median age at diagnosis is 72 years, in the last decades chronic lymphocytic leukemia is more often diagnosed also in younger individuals, with almost 15% Of patients Of 55 years old or younger. There is a gender predisposition, As men are more frequently affected by chronic lymphocytic leukemia than women (male: female ratio of 1.5-2:1).

C-X-C chemokine receptor type 4 (CXCR4) is a chemokine and chemokine receptor pair playing critical roles in tumorigenesis. Overexpression of C-X-C chemokine receptor type 4 is a hallmark of many hematological malignancies including acute myeloid leukemia, chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and generally correlates with a poor prognosis. A highly potent competitive antagonist of C-X-C chemokine receptor type 4 recently has been identified with suppression of cancer cells aggressiveness in a variety of cancers.

The protein-coupled receptor C-X-C chemokine receptor type 4 is activated by stromal cell-derived factor 1 and is involved in the control of migration and homing of cells notably for engraftment of normal and neoplastic hematopoietic cells in the bone marrow (BM).

Bruton's tyrosine kinase (BTK) is a key player in B-cell antigen receptor (BCR) signaling that regulates B-cell growth. In addition to B-cell antigen receptor signaling, Bruton's tyrosine kinase participates in signal transduction through growth-factor receptors, Toll-like receptors, integrins and G-protein-coupled receptors such as C-X-C chemokine receptor type 4 and C-X-C chemokine receptor type 5. Bruton's tyrosine kinase inhibition results in impaired C-X-C chemokine receptor type 4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. inhibition of Bruton's tyrosine kinase function would lead to a loss of tumor volume by preventing replenishment after spontaneous or drug-induced death, and by subverting leukemia cell retention in and homing back to sustaining tissue niches. Decrease C-X-C chemokine receptor type 4 delays disease progression and prolongs survival

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

From Hematology clinic with chronic lynphocytic leukemia

Description

Inclusion Criteria:

  • All patients are newly diagnosed as chronic lymphocytic leukemia

Exclusion Criteria:

  • Patients with associated malignancies.
  • Chronic lymphocytic leukemia patients on chemotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patient group
patient with chronic lymphocytic leukemia
Diagnostic test: C-X-C Chemokine Receptor 4
marker assessed by flowcytometry in a blood sample
control group
healthy control group
Diagnostic test: C-X-C Chemokine Receptor 4
marker assessed by flowcytometry in a blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The level of C-X-C Chemokine Receptor 4 in chronic lymphocytic leukemia patient and healthy individual
Time Frame: 2 years
the level of C-X-C Chemokine Receptor 4 marker assessed by flowcytometry in a blood sample
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 1, 2017

Primary Completion (Anticipated)

July 1, 2019

Study Completion (Anticipated)

December 1, 2019

Study Registration Dates

First Submitted

May 7, 2017

First Submitted That Met QC Criteria

May 11, 2017

First Posted (Actual)

May 12, 2017

Study Record Updates

Last Update Posted (Actual)

May 12, 2017

Last Update Submitted That Met QC Criteria

May 11, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • cxcll

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Lymphocytic Leukemia

Clinical Trials on C-X-C Chemokine Receptor 4

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe